tetano
Editor, Senior Moderator
Nat Med
. 2021 Oct 14.
doi: 10.1038/s41591-021-01548-7. Online ahead of print.
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B Pouwels[SUP] 1 2 [/SUP], Emma Pritchard[SUP] 3 4 [/SUP], Philippa C Matthews[SUP] 4 5 6 [/SUP], Nicole Stoesser[SUP] 3 4 5 6 [/SUP], David W Eyre[SUP] 3 4 5 7 [/SUP], Karina-Doris Vihta[SUP] 3 8 [/SUP], Thomas House[SUP] 9 10 [/SUP], Jodie Hay[SUP] 11 12 [/SUP], John I Bell[SUP] 13 [/SUP], John N Newton[SUP] 14 [/SUP], Jeremy Farrar[SUP] 15 [/SUP], Derrick Crook[SUP] 3 4 5 6 [/SUP], Duncan Cook[SUP] 16 [/SUP], Emma Rourke[SUP] 16 [/SUP], Ruth Studley[SUP] 16 [/SUP], Tim E A Peto[SUP] 3 4 5 6 [/SUP], Ian Diamond[SUP] 16 [/SUP], A Sarah Walker[SUP] 3 4 5 17 [/SUP]
Affiliations
Abstract
The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households across the United Kingdom. We found that the effectiveness of BNT162b2 and ChAdOx1 against infections (new polymerase chain reaction (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (absolute difference of 10-13% for BNT162b2 and 16% for ChAdOx1) compared to the B.1.1.7 (Alpha) variant. The effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity after second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positive cases but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher in vaccinated individuals after a prior infection and in younger adults. With B.1.617.2, infections occurring after two vaccinations had similar peak viral burden as those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with B.1.617.2.
. 2021 Oct 14.
doi: 10.1038/s41591-021-01548-7. Online ahead of print.
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B Pouwels[SUP] 1 2 [/SUP], Emma Pritchard[SUP] 3 4 [/SUP], Philippa C Matthews[SUP] 4 5 6 [/SUP], Nicole Stoesser[SUP] 3 4 5 6 [/SUP], David W Eyre[SUP] 3 4 5 7 [/SUP], Karina-Doris Vihta[SUP] 3 8 [/SUP], Thomas House[SUP] 9 10 [/SUP], Jodie Hay[SUP] 11 12 [/SUP], John I Bell[SUP] 13 [/SUP], John N Newton[SUP] 14 [/SUP], Jeremy Farrar[SUP] 15 [/SUP], Derrick Crook[SUP] 3 4 5 6 [/SUP], Duncan Cook[SUP] 16 [/SUP], Emma Rourke[SUP] 16 [/SUP], Ruth Studley[SUP] 16 [/SUP], Tim E A Peto[SUP] 3 4 5 6 [/SUP], Ian Diamond[SUP] 16 [/SUP], A Sarah Walker[SUP] 3 4 5 17 [/SUP]
Affiliations
- PMID: 34650248
- DOI: 10.1038/s41591-021-01548-7
Abstract
The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households across the United Kingdom. We found that the effectiveness of BNT162b2 and ChAdOx1 against infections (new polymerase chain reaction (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (absolute difference of 10-13% for BNT162b2 and 16% for ChAdOx1) compared to the B.1.1.7 (Alpha) variant. The effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity after second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positive cases but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher in vaccinated individuals after a prior infection and in younger adults. With B.1.617.2, infections occurring after two vaccinations had similar peak viral burden as those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with B.1.617.2.